Sanofi Fined $53M In France Over Generic Plavix Smears

Law360, New York (May 14, 2013, 1:27 PM EDT) -- France’s antitrust regulator has fined Sanofi SA €40.6 million ($52.7 million) after ruling the drugmaker had engaged in a campaign to discourage doctors and pharmacists from prescribing or substituting generic versions of its former blockbuster blood thinner Plavix, the watchdog announced Tuesday.

According to the French Competition Authority, Sanofi had abused its dominant position in the market to engage in a “strategy of denigration” against generic Plavix competitors between September 2009 and January 2010, in an attempt to limit the entry of those competitors into the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.